BriaCell Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 31, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Net Income	-34.68	-36.8	-6.81	-26.79	-34.4	-17.24
Depreciation & Amortization	0.05	0.15	0.12	0.02	0.02	0.02
Stock-Based Compensation	0.85	1.08	2.49	2.89	3.94	2.46
Other Adjustments	-0.75	-0.82	-38.85	-2.8	14.94	7.94
Change in Receivables	0.01	1.02	-1.01	0.01	-0.01	0.01
Changes in Accounts Payable	-1.86	-5.39	8.35	0.87	0.32	-1.75
Changes in Accrued Expenses	1.24	1.04	-0.53	0.26	0.17	-0.98
Changes in Other Operating Activities	1.15	0.68	2.94	-5.8	-0.98	-0.13
Operating Cash Flow	-35.99	-39.04	-33.32	-31.33	-16	-9.67
Capital Expenditures	-	-	-0.63	-	-	-
Purchases of Investments	-	-10.14	-	-	-	-
Proceeds from Sale of Investments	3.69	-	-	-	-	-
Other Investing Activities	-0.4	-0.46	-0.31	-	-	-
Investing Cash Flow	3.28	-10.6	-0.94	-	-	-
Short-Term Debt Repaid	-	-	-	-	-	-0.3
Net Short-Term Debt Issued (Repaid)	-	-	-	-	-	-0.3
Long-Term Debt Issued	-	-	-	-	-	0.27
Long-Term Debt Repaid	-	-	-	-	-	-0.38
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-	-0.11
Issuance of Common Stock	65.88	62.98	6.1	5.28	8.34	81.51
Repurchase of Common Stock	-	-	-	-0.06	-13.04	-
Net Common Stock Issued (Repurchased)	65.88	62.98	6.1	5.22	-4.69	81.51
Other Financing Activities	-	-	-	-	-0.1	-
Financing Cash Flow	65.88	62.98	6.1	5.22	-4.8	81.1
Net Cash Flow	26.72	13.35	-28.15	-26.11	-20.8	71.43
Free Cash Flow	-26.8	-28.17	-24.58	-23.74	-12.48	-7.75
Free Cash Flow Per Share	-18.06	-66.58	-224.09	-228.03	-120.86	-257.22
Levered Free Cash Flow	-13.77	-28.85	2.62	-23.82	-27.2	-16.42
Unlevered Free Cash Flow	-27.89	-29.74	-25.92	-26.79	-15.65	-9.25

Updated Jan 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.